NZCA Stock Overview
Develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Provexis plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.0095 |
| 52 Week Low | UK£0.0005 |
| Beta | 1.15 |
| 11 Month Change | 0% |
| 3 Month Change | -88.89% |
| 1 Year Change | -87.50% |
| 33 Year Change | -93.75% |
| 5 Year Change | -85.71% |
| Change since IPO | -98.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| NZCA | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 0.8% |
| 1Y | -87.5% | -5.7% | 9.1% |
Return vs Industry: NZCA underperformed the German Personal Products industry which returned -6% over the past year.
Return vs Market: NZCA underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| NZCA volatility | |
|---|---|
| NZCA Average Weekly Movement | 35.8% |
| Personal Products Industry Average Movement | 3.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NZCA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: NZCA's weekly volatility has increased from 25% to 36% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2 | Ian Ford | www.provexis.com |
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product.
Provexis plc Fundamentals Summary
| NZCA fundamental statistics | |
|---|---|
| Market cap | €16.33m |
| Earnings (TTM) | -€701.97k |
| Revenue (TTM) | €960.28k |
17.0x
P/S Ratio-23.2x
P/E RatioIs NZCA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NZCA income statement (TTM) | |
|---|---|
| Revenue | UK£801.96k |
| Cost of Revenue | UK£518.17k |
| Gross Profit | UK£283.80k |
| Other Expenses | UK£870.04k |
| Earnings | -UK£586.24k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00026 |
| Gross Margin | 35.39% |
| Net Profit Margin | -73.10% |
| Debt/Equity Ratio | 0% |
How did NZCA perform over the long term?
See historical performance and comparison